Saga Diagnostics achieved a key milestone with Medicare coverage granted for its Pathlight molecular residual disease test, designed to monitor breast cancer recurrence across all subtypes. Backed by clinical evidence from the TRACER study demonstrating high sensitivity and predictive lead time, the blood-based assay offers ultrasensitive detection, particularly benefiting early-stage and ER+ breast cancer patients. The approval advances personalized surveillance and therapy decision-making in oncology.